Pharma: Other News To Note
• Teva Pharmaceutical Industries Ltd., of Jerusalem, and Lonza Group, of Basel, Switzerland, said they decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars following a strategic review of the Teva-Lonza Joint Venture.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.